New York, June 1, 2026, 08:03 EDT
Carlsmed shares head into Monday’s U.S. premarket on the back foot after a sharp Friday drop, leaving investors to decide whether recent procedure-growth momentum is enough to steady the newly listed spine-surgery company.
The stock closed Friday at $11.42, down 3.3% on the day and about 5.7% below the prior Friday’s close of $12.11. Market data put Carlsmed’s equity value at about $306 million; the shares remain roughly 24% below the $15 price set in its July 2025 initial public offering.
The timing matters. Nasdaq’s regular session had not opened at the dateline; the exchange lists premarket trading from 4:00 a.m. to 9:30 a.m. ET and regular trading from 9:30 a.m. to 4:00 p.m. ET. June 1 is not on Nasdaq’s 2026 holiday list, after the May 25 Memorial Day closure and before the June 19 Juneteenth closure.
The next few days give traders fresh checkpoints, even without a new earnings release. Carlsmed’s annual meeting is set for June 3 in San Diego, where shareholders are scheduled to vote on two directors and the ratification of Ernst & Young as auditor.
Management is also due to meet investors at the Jefferies Global Healthcare Conference in New York on June 4, followed by healthcare conferences hosted by Goldman Sachs on June 10 and Truist on June 16. Those meetings put the focus back on 2026 revenue guidance, surgeon adoption and the pace of cash burn.
Carlsmed’s latest hard numbers came on May 5. The company reported first-quarter revenue of $16.1 million, up 58.2% from a year earlier, and raised 2026 revenue guidance to $72 million to $77 million. Net loss widened to $8.7 million from $5.7 million, while gross margin — the share of sales left after product costs — rose to 77.1%. Chief Executive Mike Cordonnier said Carlsmed began the year with “strong momentum.” Carlsmed
Executives have framed the story as one of adoption, not near-term profit. On the earnings call, Cordonnier said Carlsmed was still in the “early innings” of market penetration, while Chief Financial Officer Leonard Greenstein said production investments had cut time and costs from the system and called high-70s gross margin “sustainable.” Alpha Spread
The competitive backdrop is not gentle. Carlsmed says its personalized spine implants compete with stock implants from Medtronic, Johnson & Johnson and Globus Medical, and its own annual report warns that larger rivals have deeper sales forces, broader product portfolios and more resources. The same filing flags reimbursement, surgeon adoption and reliance on contract manufacturers as risks that could slow commercialization.
That is the downside case for the stock. If hospitals push back on cost, surgeons stick with familiar implants, or losses stay wide while revenue growth cools, Carlsmed’s small market value could cut both ways. Thin trading can magnify moves.
For now, the week’s test is simpler: whether investors treat Friday’s slide as a pause after a strong May rebound, or as a warning that guidance and product-launch promises need more proof.
